)
Visual
earnings real time
Castle Biosciences
Castle Biosciences (CSTL) investor relations material
Castle Biosciences Piper Sandler 37th Annual Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Piper Sandler 37th Annual Healthcare Conference summary2 Dec, 2025
Third-quarter performance and financial overview
Achieved 36% year-over-year revenue and volume growth in Q3 2025, driven by core dermatology and gastroenterology tests.
Adjusted gross margin was 77%, down from 82% last year, reflecting loss of squamous cell carcinoma coverage.
Net cash from operations was just under $23 million, with $287 million in cash and equivalents at quarter-end.
Reported a net loss of $0.5 million and adjusted EBITDA of $9.2 million.
Product portfolio and innovation
Five dermatology tests are available, including MyPath Melanoma, DecisionDx-Melanoma, DecisionDx-SCC, and two therapy selection tests.
DecisionDx-SCC predicts response to adjuvant radiation therapy, potentially reducing unnecessary treatments.
AdvanceAD-Tx, a new test for guiding systemic therapy in moderate to severe atopic dermatitis, launched on a limited basis.
Non-invasive scraping technique developed for atopic dermatitis testing, eliminating need for biopsies.
Collaboration with SciBase explores EIS technology to predict atopic dermatitis flares.
Market opportunity and penetration
Dermatology TAM includes $540 million for melanoma and $820 million for high-risk cutaneous squamous cell carcinoma.
Atopic dermatitis test targets 13 million US patients aged 12+, representing a significant growth opportunity.
Gastroenterology TAM is estimated at $1 billion, with 420,000 Barrett's esophagus diagnoses annually.
Achieved 30%-31% market penetration for melanoma test by Q3 2025.
Strategy to restore gross margin to 82% level
Advance ADTX: path to broad market penetration
DecisionDx-SCC: Leverage radiation therapy prediction
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- ACE
Higher margins and PAT in Q3 FY26 despite flat revenue and lower sales volumes. - GODREJAGRO
Q3 FY26 revenue reached ₹2,718.32 crore with 33.9% adjusted PAT growth and strong segment gains. - QBY
Profitability returns in 2025, driven by sector focus, AI, and international expansion. - NAZARA
EBITDA and margins rose on IP focus, but regulatory changes led to major impairment losses. - HAPPYFORGE
Stable to growing financials, strong margins, and disciplined IPO fund use with no audit concerns. - RBA
Q3 revenue rose 16.5% in India; Inspira Global to acquire a controlling stake and infuse capital. - 6674
Profits and dividends revised upward on strong battery sales and improved margins. - BOROUGE
$1.1B net profit, 37% EBITDA margin, record sales, and major restructuring drive future growth. - 8059
Record Q3 profits and strong segment growth support an upwardly revised full-year outlook. - 7011
Strong order intake and profit growth drive upward revision of FY2025 forecasts and reflect key divestiture impact.
Next Castle Biosciences earnings date
Q4 202527 Feb, 2026
Castle Biosciences
Next Castle Biosciences earnings date
Q4 202527 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
)
Frequently asked questions
Castle Biosciences, Inc., a commercial-stage dermatological cancer company, focuses to provide diagnostic and prognostic solutions for dermatological cancers. Castle Biosciences is a provider of products that assesses the response of cancer patients to treatment. The company's products include Immunoscore non-invasive test, which measures changes in proteins expressed on the surface of a person's tumor; CastleTRAC, a diagnostic tool for assessing the tissue response in four types of cutaneous T-cell lymphomas (CTCL); and CastleMAP for measuring the immune reaction to a specific drug. Castle Biosciences, Inc., is based in Friendswood, Texas.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage